Introduction
• Stereotactic Body Radiation Therapy for liver cancer 
Tolerance of adjacent intestinal mucosa is an important doselimiting issue
30 Gy in 3 fractions given here; progressed to ulceration but eventually healed in approx 3 mos
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Literature Review
• 12 studies contained both dose/volume and toxicity data from 541 patients with HCC, IHC, and/or liver mets
• Median dose: 40 Gy (range, 18-60 Gy) in 1-6 fractions
• 3 end-points chosen for pooled dose-response analysis -G3+ liver enzyme elevation as a function of MLD -G2+ general GI toxicity as a function of RX or PTV dose -G3+ general GI toxicity as a function of RX or PTV dose
• RX/PTV doses were selected because doses to specific OARs were not available in many instances. 
Dose-Response Modeling
• Modeling was performed using a probit model with maximum likelihood (ML) parameter fitting.
• The ML method determined the probit model parameters that best fit the binomial (toxicity/no-toxicity) data.
• The input data were the reported toxicity rates and corresponding dose metrics reported in each study.
• The average toxicity rate was then binned into binary outcomes to facilitate probit model estimation with ML parameter fitting. 
Grade

Special Situations
• Toxicity profile of patients with metastatic disease is different from patients with primary tumors.
• Patients with metastatic liver disease tolerate RT more than patients with primary liver tumors.
-Not enough data to model each patient cohort separately.
• GI toxicity should be a function of the dose delivered to the individual GI organs.
-In the absence of dosimetric data for each GI organ, RX or PTV doses were used. 
Factors Beyond Dose/Volume Affecting Liver and GI Toxicities
Future Studies
• Explicit studies of the toxicity differences between patients with liver mets, HCC, and IHC.
• Dose-response analysis could be improved if studies report on the achieved dose-volume metrics utilized for treatment planning.
• Minimum standards for reporting treatment outcomes should include relevant clinical and dosimetric data.
• Many journals allow for the inclusion of supplemental data that can be used to include detailed DVH data and additional dosimetric details.
